AstraZeneca (LON:AZN) Raised to “Hold” at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN) was upgraded by equities researchers at Deutsche Bank Aktiengesellschaft to a “hold” rating in a report issued on Monday, Digital Look reports.

AZN has been the topic of several other reports. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a research report on Thursday, April 4th. Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Monday. UBS Group cut their price target on AstraZeneca from £107 ($133.20) to GBX 9,900 ($123.24) and set a “sell” rating on the stock in a research report on Monday, February 12th. Barclays reaffirmed an “overweight” rating and set a £125 ($155.61) price target on shares of AstraZeneca in a research report on Monday, April 8th. Finally, Jefferies Financial Group reissued a “hold” rating and set a £110 ($136.94) target price on shares of AstraZeneca in a research note on Friday, February 16th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, AstraZeneca currently has a consensus rating of “Moderate Buy” and a consensus price target of £115.43 ($143.69).

AstraZeneca Price Performance

Shares of AZN opened at £108.95 ($135.63) on Monday. The business’s 50-day moving average is £103.42 and its two-hundred day moving average is £104.22. The company has a market capitalization of £168.87 billion, a P/E ratio of 3,591.42, a P/E/G ratio of 0.89 and a beta of 0.19. The company has a debt-to-equity ratio of 75.70, a quick ratio of 0.59 and a current ratio of 0.82. AstraZeneca has a fifty-two week low of GBX 9,461 ($117.78) and a fifty-two week high of £123.92 ($154.26).

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.